An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design

Basit Öğe Kaydı
dc.authoridKAYA, HASAN/0000-0003-3923-4026
dc.authoridDonmez, Ibrahim/0000-0002-6913-9073
dc.authoridcalapkorur, bekir/0000-0002-9760-1827
dc.authoridGul, Mehmet/0000-0001-8990-1427
dc.authoridYuksel, Murat/0000-0003-2636-5211
dc.authoridYildiz, Abdulkadir/0000-0002-2291-5071
dc.contributor.authorErtas, Faruk
dc.contributor.authorKaya, Hasan
dc.contributor.authorYildiz, Abdulkadir
dc.contributor.authorDavutoglu, Vedat
dc.contributor.authorKiris, Abdulkadir
dc.contributor.authorDinc, Lale
dc.contributor.authorKafes, Habibe
dc.date.accessioned2025-01-27T21:21:21Z
dc.date.available2025-01-27T21:21:21Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials. gov number, NCT02354456.).
dc.identifier.doi10.5543/tkda.2015.35984
dc.identifier.endpage177
dc.identifier.issn1016-5169
dc.identifier.issue2
dc.identifier.pmid25782122
dc.identifier.scopus2-s2.0-84931839870
dc.identifier.scopusqualityQ3
dc.identifier.startpage169
dc.identifier.urihttps://doi.org/10.5543/tkda.2015.35984
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28909
dc.identifier.volume43
dc.identifier.wosWOS:000421963600007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Soc Cardiology
dc.relation.ispartofTurk Kardiyoloji Dernegi Arsivi-Archives of The Turkish Society of Cardiology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectAnticoagulant agent
dc.subjectatrial fibrillation/epidemiology
dc.subjectdrug utilization
dc.subjectelectrocardiography
dc.subjectinternational normalized ratio
dc.subjectwarfarin
dc.titleAn epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu